Cargando…

Use of conventional cardiac troponin assay for diagnosis of non-ST-elevation myocardial infarction: ‘The Ottawa Troponin Pathway’

BACKGROUND: Serial conventional cardiac troponin (cTn) measurements 6–9 hours apart are recommended for non-ST-elevation MI (NSTEMI) diagnosis. We sought to develop a pathway with 3-hour changes for major adverse cardiac event (MACE) identification and assess the added value of the HEART [History, E...

Descripción completa

Detalles Bibliográficos
Autores principales: Thiruganasambandamoorthy, Venkatesh, Stiell, Ian G., Chaudry, Hina, Mukarram, Muhammad, Booth, Ronald A., Toarta, Cristian, Hebert, Guy, Beanlands, Robert S., Wells, George A., Nemnom, Marie-Joe, Taljaard, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953858/
https://www.ncbi.nlm.nih.gov/pubmed/31923216
http://dx.doi.org/10.1371/journal.pone.0226892
_version_ 1783486692730077184
author Thiruganasambandamoorthy, Venkatesh
Stiell, Ian G.
Chaudry, Hina
Mukarram, Muhammad
Booth, Ronald A.
Toarta, Cristian
Hebert, Guy
Beanlands, Robert S.
Wells, George A.
Nemnom, Marie-Joe
Taljaard, Monica
author_facet Thiruganasambandamoorthy, Venkatesh
Stiell, Ian G.
Chaudry, Hina
Mukarram, Muhammad
Booth, Ronald A.
Toarta, Cristian
Hebert, Guy
Beanlands, Robert S.
Wells, George A.
Nemnom, Marie-Joe
Taljaard, Monica
author_sort Thiruganasambandamoorthy, Venkatesh
collection PubMed
description BACKGROUND: Serial conventional cardiac troponin (cTn) measurements 6–9 hours apart are recommended for non-ST-elevation MI (NSTEMI) diagnosis. We sought to develop a pathway with 3-hour changes for major adverse cardiac event (MACE) identification and assess the added value of the HEART [History, Electrocardiogram (ECG), Age, Risk factors, Troponin] score to the pathway. METHODS: We prospectively enrolled adults with NSTEMI symptoms at two-large emergency departments (EDs) over 32-months. Patients with STEMI, unstable angina and one cTn were excluded. We collected baseline characteristics, Siemens Vista conventional cTnI at 0, 3 or 6-hours after ED presentation; HEART score predictors; disposition and ED length of stay (LOS). Adjudicated primary outcome was 15-day MACE (acute MI, revascularization, or death due to cardiac ischemia/unknown cause). We analyzed multiples of 99th percentile cut-off cTnI values (45, 100 and 250ng/L). RESULTS: 1,683 patients (mean age 64.7 years; 55.3% female; median LOS 7-hours; 88 patients with 15-day MACE) were included. 1,346 (80.0%) patients with both cTnI≤45 ng/L; and 155 (9.2%) of the 213 patients with one value≥100ng/L but both<250ng/L or ≤20% change did not suffer MACE. Among 124 patients (7.4%) with one of the two values>45ng/L but<100ng/L based on 3 or 6-hour cTnI, one patient with absolute change<10ng/L and 6 of the 19 patients with≥20ng/L were diagnosed with NSTEMI (patients with Δ10-19ng/L between first and second cTnI had third one at 6-hours). Based on the results, we developed the Ottawa Troponin Pathway (OTP) with a 98.9% sensitivity (95% CI 93.8–100%) and 94.6% specificity (95% CI 93.3–95.6%). Addition of the HEART score improved the sensitivity to 100% (95% CI 95.9–100%) and decreased the specificity to 26.5% (95% CI 24.3–28.7%). CONCLUSION: The OTP with conventional cTnI 3-hours apart, should lead to better NSTEMI identification particularly those with values >99th percentile, standardize management and reduce the ED LOS.
format Online
Article
Text
id pubmed-6953858
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-69538582020-01-21 Use of conventional cardiac troponin assay for diagnosis of non-ST-elevation myocardial infarction: ‘The Ottawa Troponin Pathway’ Thiruganasambandamoorthy, Venkatesh Stiell, Ian G. Chaudry, Hina Mukarram, Muhammad Booth, Ronald A. Toarta, Cristian Hebert, Guy Beanlands, Robert S. Wells, George A. Nemnom, Marie-Joe Taljaard, Monica PLoS One Research Article BACKGROUND: Serial conventional cardiac troponin (cTn) measurements 6–9 hours apart are recommended for non-ST-elevation MI (NSTEMI) diagnosis. We sought to develop a pathway with 3-hour changes for major adverse cardiac event (MACE) identification and assess the added value of the HEART [History, Electrocardiogram (ECG), Age, Risk factors, Troponin] score to the pathway. METHODS: We prospectively enrolled adults with NSTEMI symptoms at two-large emergency departments (EDs) over 32-months. Patients with STEMI, unstable angina and one cTn were excluded. We collected baseline characteristics, Siemens Vista conventional cTnI at 0, 3 or 6-hours after ED presentation; HEART score predictors; disposition and ED length of stay (LOS). Adjudicated primary outcome was 15-day MACE (acute MI, revascularization, or death due to cardiac ischemia/unknown cause). We analyzed multiples of 99th percentile cut-off cTnI values (45, 100 and 250ng/L). RESULTS: 1,683 patients (mean age 64.7 years; 55.3% female; median LOS 7-hours; 88 patients with 15-day MACE) were included. 1,346 (80.0%) patients with both cTnI≤45 ng/L; and 155 (9.2%) of the 213 patients with one value≥100ng/L but both<250ng/L or ≤20% change did not suffer MACE. Among 124 patients (7.4%) with one of the two values>45ng/L but<100ng/L based on 3 or 6-hour cTnI, one patient with absolute change<10ng/L and 6 of the 19 patients with≥20ng/L were diagnosed with NSTEMI (patients with Δ10-19ng/L between first and second cTnI had third one at 6-hours). Based on the results, we developed the Ottawa Troponin Pathway (OTP) with a 98.9% sensitivity (95% CI 93.8–100%) and 94.6% specificity (95% CI 93.3–95.6%). Addition of the HEART score improved the sensitivity to 100% (95% CI 95.9–100%) and decreased the specificity to 26.5% (95% CI 24.3–28.7%). CONCLUSION: The OTP with conventional cTnI 3-hours apart, should lead to better NSTEMI identification particularly those with values >99th percentile, standardize management and reduce the ED LOS. Public Library of Science 2020-01-10 /pmc/articles/PMC6953858/ /pubmed/31923216 http://dx.doi.org/10.1371/journal.pone.0226892 Text en © 2020 Thiruganasambandamoorthy et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Thiruganasambandamoorthy, Venkatesh
Stiell, Ian G.
Chaudry, Hina
Mukarram, Muhammad
Booth, Ronald A.
Toarta, Cristian
Hebert, Guy
Beanlands, Robert S.
Wells, George A.
Nemnom, Marie-Joe
Taljaard, Monica
Use of conventional cardiac troponin assay for diagnosis of non-ST-elevation myocardial infarction: ‘The Ottawa Troponin Pathway’
title Use of conventional cardiac troponin assay for diagnosis of non-ST-elevation myocardial infarction: ‘The Ottawa Troponin Pathway’
title_full Use of conventional cardiac troponin assay for diagnosis of non-ST-elevation myocardial infarction: ‘The Ottawa Troponin Pathway’
title_fullStr Use of conventional cardiac troponin assay for diagnosis of non-ST-elevation myocardial infarction: ‘The Ottawa Troponin Pathway’
title_full_unstemmed Use of conventional cardiac troponin assay for diagnosis of non-ST-elevation myocardial infarction: ‘The Ottawa Troponin Pathway’
title_short Use of conventional cardiac troponin assay for diagnosis of non-ST-elevation myocardial infarction: ‘The Ottawa Troponin Pathway’
title_sort use of conventional cardiac troponin assay for diagnosis of non-st-elevation myocardial infarction: ‘the ottawa troponin pathway’
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953858/
https://www.ncbi.nlm.nih.gov/pubmed/31923216
http://dx.doi.org/10.1371/journal.pone.0226892
work_keys_str_mv AT thiruganasambandamoorthyvenkatesh useofconventionalcardiactroponinassayfordiagnosisofnonstelevationmyocardialinfarctiontheottawatroponinpathway
AT stielliang useofconventionalcardiactroponinassayfordiagnosisofnonstelevationmyocardialinfarctiontheottawatroponinpathway
AT chaudryhina useofconventionalcardiactroponinassayfordiagnosisofnonstelevationmyocardialinfarctiontheottawatroponinpathway
AT mukarrammuhammad useofconventionalcardiactroponinassayfordiagnosisofnonstelevationmyocardialinfarctiontheottawatroponinpathway
AT boothronalda useofconventionalcardiactroponinassayfordiagnosisofnonstelevationmyocardialinfarctiontheottawatroponinpathway
AT toartacristian useofconventionalcardiactroponinassayfordiagnosisofnonstelevationmyocardialinfarctiontheottawatroponinpathway
AT hebertguy useofconventionalcardiactroponinassayfordiagnosisofnonstelevationmyocardialinfarctiontheottawatroponinpathway
AT beanlandsroberts useofconventionalcardiactroponinassayfordiagnosisofnonstelevationmyocardialinfarctiontheottawatroponinpathway
AT wellsgeorgea useofconventionalcardiactroponinassayfordiagnosisofnonstelevationmyocardialinfarctiontheottawatroponinpathway
AT nemnommariejoe useofconventionalcardiactroponinassayfordiagnosisofnonstelevationmyocardialinfarctiontheottawatroponinpathway
AT taljaardmonica useofconventionalcardiactroponinassayfordiagnosisofnonstelevationmyocardialinfarctiontheottawatroponinpathway